Lijevi i desni kolorektalni karcinom – razlike u farmakoterapiji

master's thesis

• Title (english): Left and right sided colon carcinoma - differences in pharmacotherapy
• Author: Tena Škvorc
• Mentor: Petra Turčić (mentor)
• Committee member: Petra Turčić (predsjednik povjerenstva)
• Committee member: Ivana Perković (član povjerenstva)
• Committee member: Željka Vanić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology); Zagreb
• Defense date and country: 2023-05-18, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Kolorektalni karcinom jedan je od najučestalijih maligniteta u svijetu koji bilježi vrlo visoke stope morataliteta. Jedna od podjela kolorektalnog karcinoma je i ona prema položaju primarnog tumora prema kojoj se razlikuju lijevi i desni kolorektalni karcinom. Različit položaj karcinoma očituje se razlikama u procesu razvoja tumora i molekularnim karakteristikama što rezultira različitom kliničkom prezentacijom bolesti, ali i različitim odgovorom na farmakoterapiju. Iako nije zlatni standard, farmakoterapija je iznimno bitan dio liječenja kolorektalnog karcinoma. Osim što je izbor kod reduciranja tumorske mase prije operativnog zahvata, uvodi se i kada se želi smanjiti rizik ponovnog povratka bolesti, poboljšati kvalitetu života pacijenta ili kada je to jedina opcija liječenja. Farmakoterapija kolorektalnog karcinoma obuhvaća klasične kemoterapeutike, ciljanu terapiju te inhibitore imunosnih kontrolnih točaka. Budući da je kod pojedinih lijekova primijećen različit farmakoterapijski odgovor, izbor prikladne farmakoterapije jednim će dijelom ovisiti o tome radi li se o lijevom ili desnom kolorektalnom karcinomu. Farmakoterapija kod koje je primijećena najznačajnija razlika u odgovoru u ovisnosti o položaju karcinoma je ona usmjerena na EGFR i VEGF. Zbog navedenih razlika, tijekom postavljanja dijagnoze od velike je važnosti u obzir uzeti i položaj tumora kako bi se pacijentu osigurala optimalna terapija.

Abstract (english)

Colorectal cancer is one of the most common malignancies worldwide and is associated with high mortality rates. One of the classifications of colorectal cancer is based on the location of the primary tumor, distinguishing between left-sided and right-sided colorectal cancer. The different positions of the cancer result in variations in tumor development processes and molecular characteristics, leading to distinct clinical presentations of the disease and different responses to pharmacotherapy. Although not the gold standard, pharmacotherapy plays a crucial role in the treatment of colorectal cancer. It is used to reduce tumor mass before surgical intervention, decrease the risk of disease recurrence, improve the patient's quality of life, or when it’s the only treatment option left. Pharmacotherapy for colorectal cancer includes conventional chemotherapeutics, targeted therapy, and immune checkpoint inhibitors. Since different pharmacotherapeutic responses have been observed with certain drugs, the choice of appropriate pharmacotherapy partially depends on whether it is left-sided or right-sided colorectal cancer. The pharmacotherapy that shows the most significant difference in response depending on the tumor location is directed towards EGFR and VEGF. Considering these differences, it is essential to take into account the tumor's position when establishing a diagnosis to ensure optimal therapy for the patient.

• Keywords: karcinom kolona; desni kolon; lijevi kolon; biološka terapija; EGFR inhibitori; VEGF inhibitori
• Keywords (english): colorectal carcinoma; left colon; right colon; biologic therapy; EGFR inhibitors; VEGF inhibitors
• Language: croatian
• URN:NBN: urn:nbn:hr:163:762998
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2023-05-22 12:19:01